A Dendritic Cell Cancer Vaccine of Matured Phenotype Downregulates Peripheral Regulatory T Cell Frequency and Identification of Plasma Protein Profiles Predicting Vaccine Efficacy - Results from a Phase II Study

被引：0
|
作者：
Wang, Who-Whong [1 ]
Chia, John [1 ]
Tan, Sze Huey [1 ]
Zocca, Mai-Britt [2 ]
Claesson, Mogens H. [3 ]
Toh, Han Chong [1 ]
机构：
[1] Natl Canc Ctr, Singapore, Singapore
[2] Dandrit Biotech A S, Copenhagen, Denmark
[3] Univ Copenhagen, Copenhagen, Denmark
来源：
MOLECULAR THERAPY | 2009年 / 17卷
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：S208 / S208
页数：1
相关论文
共 50 条
  • [31] Clinical phase I/IIa study with TERT and survivin double loaded dendritic cell vaccine for patients with advanced ovarian cancer: Focus on safety and immunological proof of concept results
    Imhof, M.
    Lipovac, M.
    Barta, J.
    Gomez, I.
    Haiderer, B.
    Hrdina, A.
    Krupa, E.
    Pieta, K.
    Tamregger, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S736 - S736
  • [32] Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
    Shi, Y.
    Dong, M.
    Hong, X.
    Zhang, W.
    Feng, J.
    Zhu, J.
    Yu, L.
    Ke, X.
    Huang, H.
    Shen, Z.
    Fan, Y.
    Li, W.
    Zhao, X.
    Qi, J.
    Huang, H.
    Zhou, D.
    Ning, Z.
    Lu, X.
    ANNALS OF ONCOLOGY, 2015, 26 (08) : 1766 - 1771
  • [33] PHASE I STUDY OF ADOPTIVE T CELL THERAPY FOLLOWING HER2-PULSED DENDRITIC CELL VACCINE AND PEPINEMAB/TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER (MBC)
    Han, Hyo
    Evans, Elizabeth
    Fisher, Terrence
    Soliman, Hatem
    Khong, Hung
    Soyano, Aixa
    Costa, Ricardo
    Loftus, Loretta
    Lee, Kimberley
    Armaghani, Avan
    Liu, Hien
    Locke, Frederick
    Shrewsbury, Alexandria
    Malka, Jessica
    Karyampudi, Lavakumar
    Zauderer, Maurice
    Czerniecki, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A676 - A676
  • [34] Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC)
    Han, Hyo S.
    Costa, Ricardo L.
    Soliman, Hatem Hussein
    Soyano, Aixa
    Khong, Hung T.
    Loftus, Loretta S.
    Lee, Kimberley T.
    Armaghani, Avan J.
    Liu, Hien
    Malka, Jessica
    Locke, Frederick L.
    Mo, Qianxing
    Whiting, Junmin
    Karyampudi, Lavakumar
    Evans, Elizabeth E.
    Fisher, Terrence Lee
    Zauderer, Maurice
    Czerniecki, Brian J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
    Singer, Christian F.
    Pfeiler, Georg
    Hubalek, Michael
    Bartsch, Rupert
    Stoeger, Herbert
    Pichler, Angelika
    Petru, Edgar
    Bjelic-Radisic, Vesna
    Greil, Richard
    Rudas, Margaretha
    Tea, Muy-Kheng Maria
    Wette, Viktor
    Petzer, Andreas L.
    Sevelda, Paul
    Egle, Daniel
    Dubsky, Peter C.
    Filipits, Martin
    Fitzal, Florian
    Exner, Ruth
    Jakesz, Raimund
    Balic, Marija
    Tinchon, Christoph
    Bago-Horvath, Zsuzsanna
    Frantal, Sophie
    Gnant, Michael
    EUROPEAN JOURNAL OF CANCER, 2020, 132 : 43 - 52
  • [36] Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC)
    Slawin, K. M.
    Sonpavde, G.
    McMannis, J. D.
    Bai, Y.
    Seethammagari, M.
    Bull, J. M. C.
    Hawkins, V.
    Dancsak, T.
    Lapteva, N.
    Levitt, J. M.
    Spencer, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC)
    Sonpavde, G.
    McMannis, J. D.
    Bai, Y.
    Seethammagari, M.
    Bull, J. M.
    Hawkins, V.
    Dancsak, T.
    Lapteva, N.
    Spencer, D. M.
    Slawin, K. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [38] Is there a role for autologous stem-cell transplantation (ASCT) in peripheral T-Cell lymphoma (PTCL)? Final results of a prospective phase II study from the GELCAB.
    Mercadal, Santiago
    Lopez-Guillermo, Armando
    Briones, Javier
    Xicoy, Blanca
    Pedro, Carme
    Escoda, Lourdes
    Estany, Cristina
    Camos, Mireia
    Ribera, Josep-Maria
    Martino, Rodrigo
    Colomo, Llms
    Montserrat, Emili
    BLOOD, 2006, 108 (11) : 874A - 875A
  • [39] A first in man phase I/II adjuvant dendritic cell vaccine study in high-risk prostate cancer patients following radical surgery reduce the incidence of biochemical relapse
    Tryggestad, Anne Merete
    Bigalke, Iris
    Axcrona, Karol
    Brennhovd, Bjorn
    Honnashagen, T. Kirsti
    Skoge, Lisbeth
    Tjeldhorn, Lena
    Mowinckel, Lene
    Saeboe-Larsen, Stein
    Jorgensen, Jens A. L.
    Andreassen, Grete S.
    Skorstad, Gjertrud
    Josefsen, Dag
    Axcrona, Ulrika
    Aamadal, Steinar
    Lilleby, Wolfgang
    Dueland, Svein
    Kvalheim, Gunnar
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
    Tryggestad, Anne M. A.
    Axcrona, Karol
    Axcrona, Ulrika
    Bigalke, Iris
    Brennhovd, Bjorn
    Inderberg, Else M.
    Honnashagen, Turid K.
    Skoge, Lisbeth J.
    Solum, Guri
    Saeboe-Larssen, Stein
    Josefsen, Dag
    Olaussen, Richard W.
    Aamdal, Steinar
    Skotheim, Rolf I.
    Myklebust, Tor A.
    Schendel, Dolores J.
    Lilleby, Wolfgang
    Dueland, Svein
    Kvalheim, Gunnar
    PROSTATE, 2022, 82 (02): : 245 - 253
12345